Navigation Links
ARRAYit Corporation Receives Purchase Order from ChemBio
Date:11/1/2013

SUNNYVALE, Calif., Nov. 1, 2013 /PRNewswire/ -- ARRAYit Corporation (OTCQB: ARYC) reports that it has received a $72,297 purchase order from ChemBio, the company's high-powered distributor in Moscow, Russia. ChemBio, which is Russia's premiere distributor of life sciences products and services, represents ARRAYit, Corning, Molecular Devices, Nalgene and other leading corporations, providing Russian customers with market information, technical assistance, installation, product support and training. 

ChemBio purchased the patented and proprietary ARRAYit Microarray Platform including a SpotBot® 3 Protein Edition Desktop Personal Microarrayer and 126 additional instruments, tools, kits, reagents and consumables for advanced microarray research and development. 

ARRAYit currently has a worldwide installed customer base of over 390 SpotBot® instruments, representing $8 million in aggregate revenue to the company. ARYC expects to report the sales and earnings from the ChemBio transaction in the current quarter. 

About ARRAYit Corporation                           

ARRAYit Corporation is a Sunnyvale, California-based company leading and empowering the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development, and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. The company's innovative products and services help scientists and clinicians explore the human genome as well as the genomes of plants and animals. ARRAYit's products are used by nearly every major research center in the world.

About Liston Street Pulse                                                

Liston Street Pulse is a leading provider of financial research. The company has significant expertise in U.S. listed small cap and micro-cap stocks. Subscribe here to read more about ARYC, including CEO interviews.

Safe Harbor Statement

Except for historical information contained herein, statements made in this release that constitute forward-looking statements are based on currently available information, involve certain risks and uncertainties and the Company assumes no responsibility to update any such forward-looking statement. The following factors, among others, may cause actual results to differ materially from the results suggested in the forward-looking statements. Risks that may result from changes in the Company's business operations; our ability to keep pace with technological advances; significant competition in the biomedical business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions, the outcome of our legal disputes; the possibility that the review of our prior filings by the SEC may result in changes to our financial statements; and the possibility that stockholders or regulatory authorities may initiate proceedings against ARRAYit and/or our officers and directors as a result of any restatements. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K for the fiscal year ended December 31, 2012 and Form 10-Q for the fiscal first quarter ended March 31, 2013, Form 10-Q for the fiscal second quarter ended June 30, 2013.


'/>"/>
SOURCE ARRAYit Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Arrayit Corporation Holds Successful Meeting with DHK Medical Products CEO
2. Arrayit on Major Fundraising Drive
3. Genentech Purchases Arrayit Technology
4. ARRAYit Corporation Ships Proprietary Life Sciences Products to Illumina Inc.
5. ARRAYit Corporation Ships Proprietary Life Sciences Products to Google Inc.
6. ARRAYit Corporation Receives $104,000 Purchase Order from the University of California
7. Arrayit Corporation Announces New Corporate Headquarters in Sunnyvale California
8. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
9. CVS Caremark Corporation to Hold First Quarter 2012 Conference Call
10. Richard Wolf Medical Instruments Corporation: 40 Years of Innovation
11. Haemonetics Signs Definitive Agreement to Acquire Pall Corporations Blood Collection, Filtration and Processing Product Lines For $551 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... 2016 Yissum Research Development ... today that it had signed an exclusive world-wide licensing ... of novel protein degradation and immunomodulatory drugs for cancer ... drug candidates representing first-in-class therapy for hematologic and solid ... The novel technology was developed by ...
(Date:5/4/2016)... May 4, 2016 ... the  "Global Acute Myeloid Leukemia Market and ... their offering.       (Logo: ... Leukemia Market and Competitive Landscape Highlights 2016, ... pipeline products, Acute Myeloid Leukemia epidemiology, Acute ...
(Date:5/3/2016)... Research and Markets has announced the addition ... Outlook 2020" report to their offering. ... has improved significantly in past years due to which ... years. Many cancer drugs have been developed by utilization ... expected to be developed with its help. They are ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... TIME for Kids and The ... announced a new partnership to reach nearly 1 million children with important water safety ... and is the leading cause of accidental death in children one to 6 years ...
(Date:5/5/2016)... Woodinville, WA (PRWEB) , ... May 05, 2016 ... ... better user experience, adapted to people’s every day living patterns, Amerec, a Seattle-based ... easy-to-use computer and smart phone app. , The user interface of the app, ...
(Date:5/5/2016)... ... (PRWEB) May 05, 2016 , ... Talent Tech Labs ... on the eve of National Nurses Week (May 6-12). Currently, HireNurses is ... With their enrollment into the Talent Tech Lab Virtual Incubation program, they will dramatically ...
(Date:5/5/2016)... ... 2016 , ... Chronic stress can have a silent, yet dangerous, impact on ... system and increase inflammation, both of which raise the risk of heart attack and ... program at Harvard-affiliated Massachusetts General Hospital. Chronic stress also can lead to other issues ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... finalists and winners Tuesday evening, May 3, at the 2016 ISE® Central Executive ... Scott Pettigrew, Vice President and Chief Security Officer of HMS, was selected as ...
Breaking Medicine News(10 mins):